Literature DB >> 7591581

Effect of recombinant human erythropoietin (rHuEPO) on protein, zinc (Zn), nickel (Ni) and manganese (Mn) in patients undergoing chronic haemodialysis.

S Hosokawa1, O Yoshida.   

Abstract

Serum protein, albumin, Zn, Ni and Mn concentrations were examined in thirty patients undergoing chronic haemodialysis and whose haematocrit levels had been maintained at 30% for two years with rHuEPO. Serum total protein, albumin, Zn, Ni and Mn concentrations significantly increased with time for two years with rHuEPO therapy. All patients showed improvement of appetite and a normal protein balance. Serum Zn, Ni and Mn levels increased with serum total protein. In conclusion, rHuEPO therapy is very effective for the increase of serum protein, albumin, Zn, Ni and Mn levels in patients undergoing chronic haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591581     DOI: 10.1007/BF02551322

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

Review 1.  Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.

Authors:  A R Nissenson
Journal:  Semin Nephrol       Date:  1989-03       Impact factor: 5.299

2.  Influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency.

Authors:  C Fischer; P Scigalla; W Park; H Becker; R Schiller; H Paust; H Broesicke; M Kessel
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

3.  Role of manganese in chronic hemodialysis patients.

Authors:  S Hosokawa; H Nishitani
Journal:  Int J Artif Organs       Date:  1987-01       Impact factor: 1.595

4.  Erythropoietin-induced changes in protein nutrition: quantitative assessment by urea kinetic modeling analysis.

Authors:  B Canaud; C Bouloux; J P Rivory; J Taib; L J Garred; P Florence; C Mion
Journal:  Blood Purif       Date:  1990       Impact factor: 2.614

5.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

6.  The measurement of whole body protein turnover in the preterm infant with intragastric infusion of L-[1-13C]leucine and sampling of the urinary leucine pool.

Authors:  B de Benoist; Y Abdulrazzak; O G Brooke; D Halliday; D J Millward
Journal:  Clin Sci (Lond)       Date:  1984-02       Impact factor: 6.124

7.  Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.

Authors:  B G Delano
Journal:  Am J Kidney Dis       Date:  1989-08       Impact factor: 8.860

8.  Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease.

Authors:  P Scigalla; K E Bonzel; M Bulla; R Burghard; J Dippel; J Geisert; E Leumann; T von Lilien; D E Müller-Wiefel; G Offner
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

9.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

10.  Urea kinetics in patients on regular dialysis treatment before and after treatment with recombinant human erythropoietin.

Authors:  E Zehnter; M Pollok; D Ziegenhagen; P Bramsiepe; F Longere; C A Baldamus; U Wellner; W Waters
Journal:  Contrib Nephrol       Date:  1988       Impact factor: 1.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.